On January 2, 2020 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, reported that it has been invited to present at the 38th annual JP Morgan Healthcare Conference, which takes place in San FranciscoJanuary 13-16, 2020 (Press release, Taiwan Liposome Company, JAN 2, 2020, View Source [SID1234552661]). Details of the presentation are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TLC Presentation at JP Morgan Healthcare Conference
Date: Wednesday, January 15, 2020
Time: 10:00am PST
Location: Mission Bay (32nd Floor)
Westin St. Francis Hotel
335 Powell Street, San Francisco, CA94102
2020 marks TLC’s sixth attendance in a row at the invitation-only event, which is the largest and most informative healthcare investment symposium in the industry, gathering more than 8,000 attendees. TLC will provide an update on the status of its innovative product candidates, including TLC599 for sustained release treatment of knee osteoarthritis pain and TLC590 for sustained release management of postsurgical pain, both of which are non-opioids that have the potential to become viable alternatives to highly addictive opioids.
A copy of the presentation will be available under News & Events of the Investors section on the company website at www.tlcbio.com.